On World Obesity Day Europe, Adalvo joins the healthcare community in recognising obesity as one of the most pressing public health challenges across the European Union.
More than 60% of adults in the EU are overweight or living with obesity. Classed as a complex, chronic disease by the World Health Organisation (WHO), obesity is associated with serious comorbidities including type 2 diabetes, cardiovascular disease, and 13 different cancers.
Despite decades of preventative efforts by EU governments, obesity continues to rise, placing increasing strain on patients, healthcare systems, and entire economies.
To learn more about our portfolio of metabolic and endocrine products, please contact one of the team.
Rising obesity is impacting peoples’ health, wealth and wellbeing. According to the OECD, obesity-related diseases account for 8.4% of the EU’s total health budgets, and curb GDP by 3.3%.
Addressing this requires sustained action across prevention, policy, and therapeutic innovation. Every dollar spent on preventing obesity creates an economic return that’s up to six times greater.
Advances in metabolic science, particularly GLP-1 receptor agonists, are transforming treatment approaches and expanding options for long-term management.
Adalvo’s growing peptide portfolio, including semaglutide, reflects our strategic focus on complex, high-impact molecules that address significant unmet medical needs.
In response to the rising global demand for GLP-1 therapies, we’ve developed a robust dual-sourcing strategy for key ingredients. This strengthens supply resilience and ensures continuity for our partners.
Anil Okay, CEO comments: “Together with our partners, we are lowering the cost of high-impact GLP-1 therapies while accelerating access to them for patients around the world.”
On World Obesity Day Europe, we reaffirm our commitment to advancing scientific innovation and bringing life-changing therapies to those who need them.
To see our full range of metabolic and endocrine therapies, contact one of the team today.